Aller au contenu

BioSpace

BioSpace
BioSpace
Dernier épisode

256 épisodes

  • BioSpace

    Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

    12/08/2026 | 19 min
    After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.
  • BioSpace

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

    11/08/2026 | 23 min
    The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.
  • BioSpace

    The next treatment-resistant depression paradigm

    06/08/2026 | 20 min
    In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.

    Host

    ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

    Guests

    Hans Eriksson, Chief Medical Officer, FundaMental Pharma

    Steve Levine, Chief Patient Officer, Compass Pathways

    Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
  • BioSpace

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

    05/08/2026 | 24 min
    The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.
  • BioSpace

    Life after the lead asset: Advancing an early-stage pipeline

    30/07/2026 | 24 min
    In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively.

    This episode is presented in partnership with Arvinas.

    Host
    Jennifer Smith-Parker, Director of Insights, BioSpace

    Guest
    Randy Teel, President and CEO, Arvinas
Plus de podcasts Science de la vie
À propos de BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Site web du podcast

Écoutez BioSpace, 40 ans de biologie au service de l’Histoire, par Ozyme ou d'autres podcasts du monde entier - avec l'app de radio.fr

Obtenez l’app radio.fr
 gratuite

  • Ajout de radios et podcasts en favoris
  • Diffusion via Wi-Fi ou Bluetooth
  • Carplay & Android Auto compatibles
  • Et encore plus de fonctionnalités
Applications
Réseaux sociaux
v8.13.0 | © 2007-2026 radio.de GmbH
Generated: 8/12/2026 - 11:25:52 PM